Cargando…

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

OBJECTIVE: Prediabetes and type 2 diabetes mellitus (T2DM) are believed to be common and associated with a worse metabolic profile in patients with nonalcoholic fatty liver disease (NAFLD). However, no previous study has systematically screened this population. RESEARCH DESIGN AND METHODS: We studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortiz-Lopez, Carolina, Lomonaco, Romina, Orsak, Beverly, Finch, Joan, Chang, Zhi, Kochunov, Valeria G., Hardies, Jean, Cusi, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308295/ https://www.ncbi.nlm.nih.gov/pubmed/22374640 http://dx.doi.org/10.2337/dc11-1849

Ejemplares similares

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
por: Lomonaco, Romina, et al.
Publicado: (2016)

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
por: Portillo-Sanchez, Paola, et al.
Publicado: (2016)

MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Fanous, Nada, et al.
Publicado: (2020)

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
por: Ng, Cheng Han, et al.
Publicado: (2022)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

OR02-1 Differences in HDL Particle Composition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Liver Fibrosis May Explain Higher Cardiovascular Risk
por: Collier, Timothy, et al.
Publicado: (2022)

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Del Campo, José A, et al.
Publicado: (2018)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
por: Dorairaj, Vicneswarry, et al.
Publicado: (2021)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
por: Singh, Shivaram P., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
por: Chen, Qian, et al.
Publicado: (2017)

Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice
por: Schiffrin, Mariano, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
por: Pafili, Kalliopi, et al.
Publicado: (2020)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
por: Bernstein, David, et al.
Publicado: (2022)

Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
por: Spremović Rađenović, Svetlana, et al.
Publicado: (2022)

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2010)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
por: Jamwal, Rohitash, et al.
Publicado: (2020)

PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)
por: Wang, Jing-Zhang, et al.
Publicado: (2019)

Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2022)

Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
por: Sulaiman, Siti Aishah, et al.
Publicado: (2022)

Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease
por: Hossain, Israt Ara, et al.
Publicado: (2016)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: de Vries, Marieke, et al.
Publicado: (2020)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

SUN-142 High Prevalence of NAFLD and Advanced Fibrosis in Patients with Obesity and Diabetes
por: Barb, Diana, et al.
Publicado: (2019)

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
por: Yoneda, Masato, et al.
Publicado: (2008)

Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease
por: Mirza, M. S.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qs785im110jr56q45gbtfti469